Search Within

Eytan Moshe Stein

Formats
  1. Meeting Abstract (217)
  2. Journal Article (104)
  3. Review (17)
  4. Research Letter (14)
  5. Editorial (5)
  6. Book Section (3)
  7. Guidelines (2)
  8. Correspondence (1)
  9. Miscellaneous (1)
Groups
  1. Adult Leukemia (364)
  2. Center for Hematologic Malignancies (364)
  3. Department of Medicine (364)
  4. Hematologic Malignancies, Division of (364)
  5. GSK Faculty (92)
  6. Executive Committee, Center for Hematologic Malignancies (87)

More Groups

People
  1. Martin Tallman (116)
  2. Ross Levine (75)
  3. Aaron Goldberg (41)
  4. Jan Bewersdorf (33)
  5. Andriy Derkach (31)
  6. Christopher Famulare (30)

More People

Years
  1. 2025 (14)
  2. 2024 (44)
  3. 2023 (49)
  4. 2022 (34)
  5. 2021 (31)
  6. 2020 (30)

More Years

Publications
  1. Blood (170)
  2. Journal of Clinical Oncology (23)
  3. Clinical Lymphoma, Myeloma and Leukemia (17)
  4. Haematologica (16)
  5. Blood Advances (14)
  6. Leukemia and Lymphoma (12)

More Publications

Publishers
  1. American Society of Hematology (185)
  2. Elsevier Inc. (30)
  3. American Society of Clinical Oncology (27)
  4. Ferrata Storti Foundation (16)
  5. Nature Publishing Group (15)
  6. Taylor & Francis Group (12)

More Publishers

Results (364)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Therapeutic strategies targeting aberrant RNA splicing in myeloid malignancies
    Review

    Boussi, L.; Biswas, J.; Abdel-Wahab, O.; Stein, E.
    British Journal of Haematology (2024)

    Fulltext@MSK | Save
  • Genetic risk classification for adults with AML receiving less-intensive therapies: The 2024 ELN recommendations
    Journal Article

    Döhner, H.; DiNardo, C. D.; Appelbaum, F. R.; Craddock, C.; Dombret, H.; Ebert, B. L.; Fenaux, P.; Godley, L. A.; Hasserjian, R. P.; Larson, R. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Revumenib for patients with acute leukemia: A new tool for differentiation therapy
    Review

    Yisraeli Salman, M.; Stein, E. M.
    Haematologica (2024)

    Fulltext@MSK | Save
  • Beat-AML 2024 ELN–refined risk stratification for older adults with newly diagnosed AML given lower-intensity therapy
    Journal Article

    Hoff, F. W.; Blum, W. G.; Huang, Y.; Welkie, R. L.; Swords, R. T.; Traer, E.; Stein, E. M.; Lin, T. L.; Archer, K. J.; Patel, P. A.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • TP53 Y220C mutations in patients with myeloid malignancies
    Research Letter

    Gener-Ricos, G.; Bewersdorf, J. P.; Loghavi, S.; Bataller, A.; Goldberg, A. D.; Sasaki, K.; Famulare, C.; Takahashi, K.; Issa, G. C.; Borthakur, G.; more...
    Leukemia and Lymphoma (2024)

    Fulltext@MSK | Save
  • Menin inhibitors in pediatric acute leukemia: A comprehensive review and recommendations to accelerate progress in collaboration with adult leukemia and the international community
    Review

    Cuglievan, B.; Kantarjian, H.; Rubnitz, J. E.; Cooper, T. M.; Zwaan, C. M.; Pollard, J. A.; DiNardo, C. D.; Kadia, T. M.; Guest, E.; Short, N. J.; more...
    Leukemia (2024)

    Fulltext@MSK | Save
  • Cell-free DNA from nail clippings as source of normal control for genomic studies in hematologic malignancies
    Journal Article

    Krystel-Whittemore, M.; Petrova-Drus, K.; Ptashkin, R. N.; Ewalt, M. D.; Yao, J.; Liu, Y.; Zhu, M.; Benhamida, J.; Durham, B.; Kumar, J.; more...
    Haematologica (2024)

    Fulltext@MSK | Save
  • Aberrant pre-mRNA processing in cancer
    Review

    Biswas, J.; Boussi, L.; Stein, E.; Abdel-Wahab, O.
    Journal of Experimental Medicine (2024)

    Fulltext@MSK | Save
  • Intensive induction chemotherapy vs hypomethylating agents in combination with venetoclax in NPM1-mutant AML
    Journal Article

    Bewersdorf, J. P.; Shimony, S.; Shallis, R. M.; Liu, Y.; Berton, G.; Schaefer, E. J.; Zeidan, A. M.; Goldberg, A. D.; Stein, E. M.; Marcucci, G.; more...
    Blood Advances (2024)

    Fulltext@MSK | Save
  • Safety, pharmacokinetics (PK), pharmacodynamics (PD) and efficacy of KT-253, a targeted protein degrader of MDM2, in patients with relapsed/refractory (R/R) solid tumors, lymphoma, high grade myeloid malignancies and acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Khawaja, Mrruh; Naqash, A. R.; Schneider, R.; Shastri, A.; Stahl, M.; Moser, J. C.; Karim, N. F. A.; Madanat, Y.; Jonas, B. A.; Stein, E.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save